News from castle creek pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 16, 2019, 08:30 ET Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science

Castle Creek Pharmaceutical Holdings, Inc. ("CCP Holdings"), a privately held company focused on developing medicine for important rare genetic...


Sep 12, 2019, 18:35 ET Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell

Castle Creek Pharmaceutical Holdings, Inc. ("CCP Holdings") today announced it has reached an agreement to acquire Fibrocell Science, Inc. (Nasdaq:...


Jun 03, 2019, 08:30 ET Castle Creek Pharmaceuticals Appoints Mary Spellman, M.D., as Chief Medical Officer and Senior Vice President of Research & Development

Castle Creek Pharmaceuticals, LLC., a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or...


Aug 09, 2018, 08:30 ET Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex

Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and...


Jun 25, 2018, 08:30 ET Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other...


May 16, 2018, 08:30 ET Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other...


Jan 03, 2018, 08:30 ET Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other...


Oct 30, 2017, 08:00 ET Castle Creek Pharmaceuticals Announces Hiring of Dr. Amir Tavakkol as Executive Vice President and Chief Development Officer

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other...


Oct 27, 2017, 08:00 ET Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other...


Sep 27, 2017, 08:30 ET Castle Creek Pharmaceuticals Announces First IGA Scale for Epidermolysis Bullosa Simplex Clinical Research

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other...


Jun 05, 2017, 08:30 ET Castle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other...


Mar 06, 2017, 07:30 ET Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck...